EA006232B1 - Стрептококковые антигены - Google Patents
Стрептококковые антигены Download PDFInfo
- Publication number
- EA006232B1 EA006232B1 EA200201280A EA200201280A EA006232B1 EA 006232 B1 EA006232 B1 EA 006232B1 EA 200201280 A EA200201280 A EA 200201280A EA 200201280 A EA200201280 A EA 200201280A EA 006232 B1 EA006232 B1 EA 006232B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- polypeptide
- vun
- polynucleotide
- amino acid
- polypeptides
- Prior art date
Links
- 108091007433 antigens Proteins 0.000 title abstract description 16
- 102000036639 antigens Human genes 0.000 title abstract description 16
- 241000194017 Streptococcus Species 0.000 title abstract description 6
- 239000000427 antigen Substances 0.000 title description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 238
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 231
- 229920001184 polypeptide Polymers 0.000 claims abstract description 228
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 62
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 62
- 239000002157 polynucleotide Substances 0.000 claims abstract description 62
- 208000015181 infectious disease Diseases 0.000 claims abstract description 38
- 229960005486 vaccine Drugs 0.000 claims abstract description 21
- 241001465754 Metazoa Species 0.000 claims abstract description 13
- 208000035143 Bacterial infection Diseases 0.000 claims abstract 7
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract 7
- 238000011321 prophylaxis Methods 0.000 claims abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 239000013598 vector Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 18
- 239000002671 adjuvant Substances 0.000 claims description 10
- 206010035664 Pneumonia Diseases 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 8
- 230000003248 secreting effect Effects 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 5
- 230000037430 deletion Effects 0.000 claims description 5
- 201000009906 Meningitis Diseases 0.000 claims description 4
- 206010033078 Otitis media Diseases 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000003556 assay Methods 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 163
- 239000012634 fragment Substances 0.000 description 64
- 102000004169 proteins and genes Human genes 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 54
- 239000000047 product Substances 0.000 description 46
- 239000013615 primer Substances 0.000 description 44
- 230000003053 immunization Effects 0.000 description 36
- 238000002649 immunization Methods 0.000 description 36
- 241000699670 Mus sp. Species 0.000 description 33
- 238000003752 polymerase chain reaction Methods 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 125000000539 amino acid group Chemical group 0.000 description 25
- 150000001413 amino acids Chemical class 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 23
- 125000003729 nucleotide group Chemical group 0.000 description 23
- 230000001681 protective effect Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 17
- 101100292404 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MTF2 gene Proteins 0.000 description 15
- 206010061372 Streptococcal infection Diseases 0.000 description 15
- 102000037865 fusion proteins Human genes 0.000 description 15
- 108020001507 fusion proteins Proteins 0.000 description 15
- 108091008146 restriction endonucleases Proteins 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 238000010367 cloning Methods 0.000 description 13
- 230000034994 death Effects 0.000 description 13
- 231100000517 death Toxicity 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 13
- 238000002703 mutagenesis Methods 0.000 description 12
- 231100000350 mutagenesis Toxicity 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000002163 immunogen Effects 0.000 description 11
- 239000012472 biological sample Substances 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 238000012163 sequencing technique Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 239000003155 DNA primer Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 239000003298 DNA probe Substances 0.000 description 5
- 208000035109 Pneumococcal Infections Diseases 0.000 description 5
- 241000287531 Psittacidae Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000701959 Escherichia virus Lambda Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 208000022218 streptococcal pneumonia Diseases 0.000 description 4
- -1 synthetic multimers) Polymers 0.000 description 4
- 108010042407 Endonucleases Proteins 0.000 description 3
- 102000004533 Endonucleases Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 150000001412 amines Chemical group 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229940124733 pneumococcal vaccine Drugs 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 230000037432 silent mutation Effects 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 101150081058 CPR gene Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020003215 DNA Probes Proteins 0.000 description 2
- 102100035863 E3 SUMO-protein ligase ZNF451 Human genes 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 101000782473 Homo sapiens E3 SUMO-protein ligase ZNF451 Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000007330 chocolate agar Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- MURGITYSBWUQTI-UHFFFAOYSA-N fluorescin Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC=C(O)C=C2OC2=CC(O)=CC=C21 MURGITYSBWUQTI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000001718 repressive effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150000874 11 gene Proteins 0.000 description 1
- 101150082072 14 gene Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710117545 C protein Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010060123 Conjugate Vaccines Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000836268 Homo sapiens U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940031670 conjugate vaccine Drugs 0.000 description 1
- 101150037524 cop gene Proteins 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21268300P | 2000-06-20 | 2000-06-20 | |
| PCT/CA2001/000908 WO2001098334A2 (en) | 2000-06-20 | 2001-06-19 | Streptococcus antigens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200201280A1 EA200201280A1 (ru) | 2003-06-26 |
| EA006232B1 true EA006232B1 (ru) | 2005-10-27 |
Family
ID=22792041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200201280A EA006232B1 (ru) | 2000-06-20 | 2001-06-19 | Стрептококковые антигены |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP2281891A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5051959B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR100927767B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101260149B (cg-RX-API-DMAC7.html) |
| AR (1) | AR033980A1 (cg-RX-API-DMAC7.html) |
| AU (2) | AU7038101A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2413450C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ2003154A3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA006232B1 (cg-RX-API-DMAC7.html) |
| HU (1) | HU228706B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL153558A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA03000103A (cg-RX-API-DMAC7.html) |
| NO (1) | NO331103B1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ553554A (cg-RX-API-DMAC7.html) |
| PL (1) | PL214229B1 (cg-RX-API-DMAC7.html) |
| TR (1) | TR200704553T2 (cg-RX-API-DMAC7.html) |
| UY (1) | UY26783A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2001098334A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
| US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
| AU2002351623A1 (en) * | 2001-12-20 | 2003-07-09 | Shire Biochem Inc. | Streptococcus antigens |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| ES2707499T3 (es) | 2005-12-22 | 2019-04-03 | Glaxosmithkline Biologicals Sa | Vacuna de conjugado de polisacárido neumocócico |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| PT2097102E (pt) | 2006-09-07 | 2012-08-03 | Glaxosmithkline Biolog Sa | Vacina de combinação tendo quantidades reduzidas de antigénio de poliovírus |
| MX2009011837A (es) | 2007-05-02 | 2010-04-22 | Glaxosmithkline Biolog Sa | Vacuna. |
| EA201391788A1 (ru) | 2007-06-26 | 2014-08-29 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| CA2694466A1 (en) * | 2007-07-23 | 2009-01-29 | Sanofi Pasteur Limited | Immunogenic polypeptides and monoclonal antibodies |
| HUE026586T2 (hu) | 2008-04-16 | 2016-06-28 | Glaxosmithkline Biologicals Sa | Vakcina |
| CN102223876A (zh) | 2008-09-26 | 2011-10-19 | 纳米生物公司 | 纳米乳剂治疗性组合物及其使用方法 |
| KR101450958B1 (ko) | 2009-04-30 | 2014-10-15 | 콜레이 파마시티컬 그룹, 인코포레이티드 | 폐렴구균 백신 및 그의 용도 |
| US8668911B2 (en) | 2009-05-14 | 2014-03-11 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| US20120135037A1 (en) | 2009-06-01 | 2012-05-31 | Mizel Steven B | Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same |
| PT2473605T (pt) | 2009-09-03 | 2018-05-28 | Pfizer Vaccines Llc | Vacina pcsk9 |
| GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB201003920D0 (en) * | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
| KR101272351B1 (ko) | 2010-04-23 | 2013-06-07 | 이화여자대학교 산학협력단 | 새로운 카나마이신 화합물, 카나마이신 생산 스트렙토마이세스 속 미생물 및 카나마이신의 생산 방법 |
| US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
| CA2834834A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
| US11708411B2 (en) | 2013-12-20 | 2023-07-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| HRP20211288T1 (hr) | 2014-01-21 | 2021-11-26 | Pfizer Inc. | Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| DK3096783T3 (da) | 2014-01-21 | 2021-08-02 | Pfizer | Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf |
| PE20161095A1 (es) | 2014-01-21 | 2016-10-26 | Pfizer | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos |
| WO2015121783A1 (en) | 2014-02-14 | 2015-08-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
| HRP20230416T1 (hr) | 2015-01-15 | 2023-07-07 | Pfizer Inc. | Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka |
| KR20250058066A (ko) | 2015-07-21 | 2025-04-29 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| MX392525B (es) | 2017-01-20 | 2025-03-12 | Pfizer | Composiciones inmunogenicas para su uso en vacunas neumococicas |
| US20200222550A1 (en) | 2017-01-31 | 2020-07-16 | Merck Sharp & Dohme Corp. | Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f |
| EP3576784B1 (en) | 2017-01-31 | 2025-09-24 | Merck Sharp & Dohme LLC | Methods for making polysaccharide-protein conjugates |
| EP4656650A2 (en) | 2017-02-24 | 2025-12-03 | Merck Sharp & Dohme LLC | Pneumococcal conjugate vaccine formulations |
| JP7438102B2 (ja) | 2017-09-07 | 2024-02-26 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| MX2020005779A (es) | 2017-12-06 | 2020-10-28 | Merck Sharp & Dohme | Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos. |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2020121159A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
| AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| KR20220042378A (ko) | 2019-07-31 | 2022-04-05 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균 다당류-단백질 접합체 조성물 및 그 사용 방법 |
| KR20220092572A (ko) | 2019-11-01 | 2022-07-01 | 화이자 인코포레이티드 | 에스케리키아 콜라이 조성물 및 그 방법 |
| CN115362177A (zh) | 2020-02-21 | 2022-11-18 | 辉瑞公司 | 糖类的纯化 |
| EP4107170A2 (en) | 2020-02-23 | 2022-12-28 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP2023546446A (ja) | 2020-10-22 | 2023-11-02 | ファイザー・インク | 細菌多糖を精製する方法 |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| WO2022090893A2 (en) | 2020-10-27 | 2022-05-05 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| MX2023005221A (es) | 2020-11-04 | 2023-05-16 | Pfizer | Composiciones inmunogenicas para uso en vacunas neumococicas. |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| TW202245835A (zh) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物 |
| EP4333879A1 (en) | 2021-05-03 | 2024-03-13 | Pfizer Inc. | Vaccination against bacterial and betacoronavirus infections |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| BR112023023671A2 (pt) | 2021-05-28 | 2024-02-06 | Pfizer | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos |
| EP4346893A2 (en) | 2021-05-28 | 2024-04-10 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN118510548A (zh) | 2022-01-13 | 2024-08-16 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| JP2025516536A (ja) | 2022-05-11 | 2025-05-30 | ファイザー・インク | 保存剤を用いたワクチン製剤を作製するためのプロセス |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| AU2023385908A1 (en) | 2022-11-22 | 2025-05-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
| EP4661911A1 (en) | 2023-02-10 | 2025-12-17 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024201324A2 (en) | 2023-03-30 | 2024-10-03 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121057590A (zh) | 2023-04-14 | 2025-12-02 | 辉瑞公司 | 包含缀合荚膜糖抗原的免疫原性组合物及其用途 |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| AU2024271872A1 (en) | 2023-05-18 | 2025-12-18 | Merck Sharp & Dohme Llc | Compounds and adjuvant formulations useful in pneumococcal vaccines |
| WO2024241172A2 (en) | 2023-05-19 | 2024-11-28 | Glaxosmithkline Biologicals Sa | Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection |
| WO2025057078A1 (en) | 2023-09-14 | 2025-03-20 | Pfizer Inc. | Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof |
| WO2025106603A1 (en) | 2023-11-16 | 2025-05-22 | Merck Sharp & Dohme Llc | Peptide conjugate vaccine compositions and methods for the treatment of alzheimer's disease |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025191415A1 (en) | 2024-03-11 | 2025-09-18 | Pfizer Inc. | Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof |
| WO2025219908A2 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Media and fermentation methods for polysaccharide production in bacterial cell culture |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4431739A (en) | 1979-11-05 | 1984-02-14 | Genentech, Inc. | Transformant bacterial culture capable of expressing heterologous protein |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| EP0831894A1 (en) * | 1995-06-07 | 1998-04-01 | Alberta Research Council | Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them |
| DE69739981D1 (de) * | 1996-10-31 | 2010-10-14 | Human Genome Sciences Inc | Streptococcus pneumoniae-Antigene und Impfstoffe |
| CN1291233A (zh) * | 1997-09-24 | 2001-04-11 | 美国明尼苏达州大学 | 来自肺炎链球菌之人类补体c3降解蛋白酶 |
| WO2000006737A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | Streptococcus pneumoniae proteins and nucleic acid molecules |
| WO2000010599A2 (en) * | 1998-08-19 | 2000-03-02 | North American Vaccine, Inc. | IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE |
| JP2002526082A (ja) * | 1998-09-24 | 2002-08-20 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | ストレプトコッカス・ニューモニア由来のヒト補体ｃ３分解ポリペプチド |
| DE69940439D1 (de) * | 1998-12-21 | 2009-04-02 | Medimmune Inc | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe |
| NZ512574A (en) * | 1998-12-23 | 2004-03-26 | Iaf Biochem Int | Novel streptococcus antigens useful as vaccines |
-
2001
- 2001-06-19 EP EP10179497A patent/EP2281891A3/en not_active Withdrawn
- 2001-06-19 JP JP2002504289A patent/JP5051959B2/ja not_active Expired - Fee Related
- 2001-06-19 MX MXPA03000103A patent/MXPA03000103A/es active IP Right Grant
- 2001-06-19 KR KR1020027017453A patent/KR100927767B1/ko not_active Expired - Fee Related
- 2001-06-19 AU AU7038101A patent/AU7038101A/xx not_active Withdrawn
- 2001-06-19 NZ NZ553554A patent/NZ553554A/en not_active IP Right Cessation
- 2001-06-19 CN CN200710181645.XA patent/CN101260149B/zh not_active Expired - Fee Related
- 2001-06-19 HU HU0301656A patent/HU228706B1/hu not_active IP Right Cessation
- 2001-06-19 CA CA2413450A patent/CA2413450C/en not_active Expired - Fee Related
- 2001-06-19 TR TR2007/04553T patent/TR200704553T2/xx unknown
- 2001-06-19 PL PL360413A patent/PL214229B1/pl unknown
- 2001-06-19 EA EA200201280A patent/EA006232B1/ru not_active IP Right Cessation
- 2001-06-19 CZ CZ2003154A patent/CZ2003154A3/cs unknown
- 2001-06-19 WO PCT/CA2001/000908 patent/WO2001098334A2/en not_active Ceased
- 2001-06-19 IL IL15355801A patent/IL153558A0/xx unknown
- 2001-06-19 AU AU2001270381A patent/AU2001270381B2/en not_active Ceased
- 2001-06-19 EP EP01949136A patent/EP1303612A2/en not_active Withdrawn
- 2001-06-19 CN CN01814388A patent/CN1449446A/zh active Pending
- 2001-06-20 UY UY26783A patent/UY26783A1/es not_active Application Discontinuation
- 2001-06-20 AR ARP010102945A patent/AR033980A1/es not_active Application Discontinuation
-
2002
- 2002-12-19 IL IL153558A patent/IL153558A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026121A patent/NO331103B1/no not_active IP Right Cessation
-
2012
- 2012-05-23 JP JP2012117846A patent/JP5889103B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA006232B1 (ru) | Стрептококковые антигены | |
| Brodeur et al. | Identification of group B streptococcal Sip protein, which elicits cross-protective immunity | |
| US5871943A (en) | Immunoassay comprising a truncated pneumococcal surface protein A (PspA) | |
| EP0571538B1 (en) | Structural gene of pneumococcal protein | |
| CN100398653C (zh) | 新颖的链球菌抗原 | |
| US20030099673A1 (en) | Membrane-associated immunogens of mycobacteria | |
| US6426074B1 (en) | Group B Streptococcus vaccine | |
| WO2003054007A2 (en) | Streptococcus antigens | |
| AU682018B2 (en) | Epitopic regions of pneumococcal surface protein A | |
| EA015561B1 (ru) | НОВЫЙ ПОВЕРХНОСТНЫЙ БЕЛОК HAEMOPHILUS INFLUENZAE (БЕЛОК E; pE) | |
| KR19990022742A (ko) | 스트렙토코커스 속 유래의 hsp70 계열의 쇼크 단백질 | |
| AU693175B2 (en) | Epitopic regions of pneumococcal surface protein A | |
| US6737521B1 (en) | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria | |
| JPH09506247A (ja) | ヘモフィリス属菌株トランスフェリン受容体遺伝子 | |
| AU2008204471B2 (en) | Protective proteins of S. agalactiae, combinations thereof and methods of using the same | |
| EP0669985A1 (en) | Conjugate vaccine against group b streptococcus | |
| AU674311B2 (en) | Delivery and expression of a hybrid surface protein on the surface of gram positive bacteria | |
| HUT64596A (en) | Recombinant vaccine against swine pleuropneumonie | |
| Kling et al. | Characterization of two distinct opsonic and protective epitopes within the alpha C protein of the group B Streptococcus | |
| KR20200135563A (ko) | 박테리아 표면 수용체 단백질로부터 유래된 면역원성 조성물 및 백신 | |
| JPH10509865A (ja) | 細菌膜上で発現される呼吸器多核体ウイルスプロテインｇ | |
| KR20080052693A (ko) | 유전자, 단백질 및 그들의 용도 | |
| WO2003059252A2 (en) | Use of a novel cell surface protease from group b streptococcus | |
| AU667668C (en) | Structural gene of pneumococcal protein | |
| JP4184430B2 (ja) | プロテアーゼ活性低下型のＨａｅｍｏｐｈｉｌｕｓ Ｈｉｎ４７の類似体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1A | Registration of transfer to a eurasian application by force of assignment | ||
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): KZ |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): BY RU |